21st Annual Conference of the British HIV Association (BHIVA)



Dr Sonia Raffe

Royal Sussex County Hospital, Brighton

21st Annual Conference of the British HIV Association (BHIVA)



Dr Sonia Raffe

Royal Sussex County Hospital, Brighton

Speaker Name	Statement
Dr Sonia Raffe	None
Date	April 2015

Pregnancies in women with HIV

Audit using data collected for the National Study of HIV in Pregnancy and Childhood

Method

- The National Study on HIV in Pregnancy and Childhood (NSHPC) provided BHIVA with anonymised data on pregnancies in the UK and Ireland
- Pregnancies with an estimated date of delivery (EDD)
 between 1 January 2013 and 30 June 2014 were included
- BHIVA audited the data against outcomes specified in its
 2012 pregnancy guidelines


NSHPC confidential pregnancy notification Form date: 07/14 Www.ucl.ac.uk/nshpc	NSHPC outcome of notified pregnancy MREC approval ref: MREC/04/2/009 torm date: 11/12 www.ucl.ac.uk/nshpc
CONFIDENTIAL	CONFIDENTIAL
Voman's date of birth:// Hospital number (or other ref): Soundex .	Your ref: EDD: Hospital of delivery
Previous livebirths stillbirths miscs/terms	Livebirth or Stillbirth Date// Male Female Gestwks Birthweightkg
thnic origin	Hospital no
PROBABLE SOURCE OF MATERNAL INFECTION	Pregnancy complications None Pre-eclampsia* Gest. diabetes Other* *please give details overlea
Maternal infection probably acquired: In UK/Ireland Abroad, specify	Invasive procedures in pregnancy None Amniocentesis CVS Cordocentesis
ikely exposure: Heterosexual - specify partner's likely risk factor, if known	Date of procedure// Viral load at time of procedurecopies/ml on//
Vertical transmission, place and age at diagnosis	Mode of delivery 1. Elective CS to prevent mother-to-child transmission 2. Planned vaginal delivery 3. Elective CS for any other reason 4. Unplanned vaginal delivery 5. Emergency CS
TIMING OF DIAGNOSIS Date of first positive test: / / If type 2 only, please tick here	Reason for delivery by 3, 4 or 5:
Diagnosed when: During this pregnancy Before this pregnancy	What was planned mode of delivery? Vaginal Elective CS Not known
Diagnosed where: Antenatal GUM clinic Other	Invasive procedures at delivery tick all that apply
any evidence of seroconversion in this pregnancy? No Yes, specify details overleaf Not known	None Ventouse Forceps, type Scalp monitor FBS
PREGNANCY Antenatal booking date:// EDD// and/or LMP//	Rupture of membranes Yes, duration
Continuing to term - if continuing, planned mode of delivery: Vaginal CS Not yet decided	Congenital abnormalities No Yes, specify
Miscarriage 3 Date of misc/TOP:/ at weeks gestation	Any other perinatal problems No Yes, specify
Termination	DRUG TREATMENT DURING PREGNANCY (continue overleaf if necessary)
PRUG TREATMENT DURING THIS PREGNANCY Vas this woman on antiretroviral drugs when she became pregnant? Yes No	Ante-partum treatment No Yes, reason (if known) Prevention of mother-to-child transmission only
old she receive antiretroviral drugs in pregnancy? Not yet Yes No Declined	Maternal health <i>and</i> prevention of transmission
Please provide details of antiretrovirals: Before preg? Date started (or gest week) Date stopped (or gest week)	Antiretrovirals Date started (or gest week) Date stopped (or gest week) Drug 1
(please circle) (if in pregnancy) Orug 1	Drug 2
Orug 2	Drug 3
Orug 3	Drug 4
Orug 4	Drug 5
Orug 5 //	Any other significant drugs (eg. PCP prophylaxis, TB treatment, methadone, illicit drugs) Drug 1date / / Drug 2date / /
MATERNAL CLINICAL STATUS	Additional treatment intra-partum None IV AZT Single dose nevirapine Other oral antiretrovirals
CDC Stage C disease ever? No Yes* if yes, date of onset://	Post-partum for infant None Oral AZT IV AZT Triple, specify
exual health screening test in this pregnancy? No Yes*, 1st screen date this preg://	MATERNAL CLINICAL STATUS If woman has died date of death / /
Concurrent maternal infection(s)? None HBV HCV Syphilis Other, specify	Symptomatic at delivery No Yes, details
MATERNAL TEST RESULTS first test results available this pregnancy	MATERNAL TEST RESULTS NEAR DELIVERY last before delivery if possible
	Viral load
form completed by: Name Date / /	Form completed by: Name Date/ _/
form completed by: Name Date// Position Telephone Email	Role/position Telephone Email
Ostion Felephone Felephone	Thank you for your help. Please return this form to: Surveillance Studies Group, MRC Centre of Epidemiology for Child Health, UCL Institute of

Results


1483 pregnancies in 1469 women

	Number of women	Percent of women
Ethnicity:		
Black African	1083	73.7%
White	250	17.0%
Black Caribbean	46	3.1%
Other/not stated	90	6.1%
Age at EDD:		
16-19	12	0.8%
20-29	344	23.4%
30-39	952	64.8%
40 or over	161	11.0%
HIV acquisition:		
Heterosexual	1251	85.2%
Vertical	21	1.4%
Injecting drug use	17	1.2%
Other/not stated	180	12.3%

HIV diagnosis and ART status



Timing of HIV diagnosis: 217 diagnosed during current pregnancy



Choice of ART regimen

Conceived on ART

Continue (intensify/switch if on PI monotherapy or D4T/DDI)

920 (62.5%)

Naïve, CD4 <350 or other maternal need for ART

TFV/FTC, ABC/3TC or ZDV/3TC, + EFV, NVP (if CD4 <250 cells/mm³)

214 (14.5%)

Naïve, mother does not need ART:

or bPI

VL >100,000

TFV/FTC, ABC/3TC or ZDV/3TC + bPl 7

VL 10,000-100,000

As above or ZDV/3TC/ABC

VL <10,000

As above, or ZDV monotherapy

338 (22.8%)

Booked after 28 weeks, VL unknown or >100,000 copies/ml

3-4 drug regimen, suggest include raltegravir

2 (0.1%)

Conceived off ART, CD4
<350 or other maternal</p>
need for ART

TFV/FTC, ABC/3TC or ZDV/3TC, + EFV, NVP (if CD4 <250 cells/mm³)

214

or bPI

Recommended NRTIs + EFV, NVP or bPI	178
Recommended NRTIs + bPI + RTG	17
Recommended NRTIs + RTG	3
More intensive	2
Recommended NRTIs + unboosted PI	3
Different NRTIs + bPI	2
ZDV/3TC/ABC	1
ZDV	1
Other or unspecified	5
None reported	2

94% compliant with guidelines

3% non-compliant with guidelines

3% unknown / not reported

338

Conceived off ART, mother does not need ART:

VL > 100,000 TFV/FTC, ABC/3TC or ZDV/3TC + bPI

VL 10,000-100,000 As above or ZDV/3TC/ABC

VL <10,000 As above, or ZDV monotherapy

Conceived off ART, mother does not need ART:				
VL >100,000	TFV/FTC, ABC/3TC or ZDV/3TC + bPI	11		
VL 10,000-100,000	As above or ZDV/3TC/ABC	81		
VL <10,000	As above, or ZDV monotherapy	162		
VL not recorded		84		

Conceived on Arri, mon	iei does not need ANI.		١
VL >100,000	TFV/FTC, ABC/3TC or ZDV/3TC + bPI	11	
VL 10,000-100,000	As above or ZDV/3TC/ABC	81	
VL <10,000	As above, or ZDV monotherapy	162	
VL not recorded		84	

	All	<10,000	10,000-100,000	>100,000
ART*	293 (87%)	132 (82%)	79 (98%)	11 (100%)
ART, unboosted PI	1 (<1%)	1 (<1%)	0	0
Triple NRTI	22 (7%)	19 (12%)	1 (1%)	0
ZDV monotherapy	9 (3%)	8 (5%)	0	0
Other	2 (<1%)	1 (<1%)	0	0
None recorded	11 (3%)	1 (<1%)	1 (1%)	0

98% 99% 100% compliant compliant

Booked after 28 weeks, VL unknown or >100,000 copies/ml

3-4 drug regimen, suggest include raltegravir

2

Only two women booked after 28 weeks with VL >100,000 copies/ml

Both started intensive regimens containing raltegravir

100% compliant with guidelines

Further ART points

- 9 women started NVP and had a reported CD4>250 cells/mm³
- Raltegravir was included in 1st regimen in:
 - 5.1% of pregnancies overall
 - 15.3% of pregnancies with ART started at VL >30,000 copies/ml
- 73 women started on darunavir during pregnancy despite it not being a preferred agent. 2014 guidelines advise considering twice daily dosing

No reported ART

- No ART was reported in 12 pregnancies
 - 8 were ongoing at last report with incomplete information;
 ART might have been used
- The remaining 4 resulted in live births:
 - 2: ART declined, delivered by elective CS
 - 1: HIV diagnosed in labour, delivered vaginally
 - 1: known HIV positive, not booked for antenatal care, delivered vaginally

Timing of ART initiation

ART needed for maternal health

Start as soon as possible, audit start date within 2 weeks of diagnosis

214

ART for prevention MTCT:

VL <30,000*

Start by beginning of week 24

402

ART for prevention MTCT:

VL >30,000

Start by beginning of week 16

123

ART	need	led	for
mate	ernal	hea	alth

Start as soon as possible, audit start date within 2 weeks of diagnosis

214

405	1.	1 1 •	• . 1	CD 4 .250
105 Wamen	Were diagnosi	ad diiring nra	agnancy with	(1)/1 < 350
TOO WOULD	were diagnose	cu during pro	sgriancy with	CD4 \330

Started within 14 days of diagnosis 30
Started at 15-28 days of diagnosis 25
Started ART at 29 days or more after diagnosis 43
Start date or diagnosis date unknown 7

29% within 2 weeks

108 women were diagnosed HIV positive before conception with CD4 <350

Started before or within 14 days of booking 33

Started at 15-28 days of booking 13

Started ART at 29 days or more after diagnosis 44

Start date or booking date unknown 18

1 woman – timing of diagnosis unclear, start date unknown

ART for prevention MTCT:

VL <30,000*

Start by beginning of week 24


402


ART for prevention MTCT:

VL >30,000

Start by beginning of week 16

123






Sexual health screening

BHIVA guideline - sexual health screening

Guidelines: Recommend near start of pregnancy if newly diagnosed, suggest for all. Consider repeat at 28 weeks.

SH screening was added to NSHPC for this audit, and its reporting increased over time

SH screening by EDD quarter:



■ Reported screened; ■ Reported not screened; ■ Not reported.

Mode of delivery

ART, VL \leq 50 at \geq 36 weeks

Plan vaginal delivery

ART, VL 50-399 at \geq 36 weeks

Consider caesarean section taking account of individual factors

ART, $VL \ge 400$ at ≥ 36 weeks

Plan caesarean section

ZDV monotherapy:

except elite controllers

Plan caesarean section

elite controllers who

Vaginal delivery acceptable

maintain VL <50

untreated

Availability of VL data

Excluding 5 stillbirths and 124 pregnancies for which outcome data not yet reported:

	Number (%) of pregnancies resulting in live birth
Total	1354 (100%)
VL reported between 36 weeks and delivery	613 (45%)
VL reported at 34-35 weeks	287 (21%)
VL reported earlier in pregnancy	398 (29%)
No reported VL in current pregnancy	56 (4%)

ART, VL \leq 50 at \geq 36 weeks

Plan vaginal delivery

1134 women had a VL ≤ 50 copies/ml at some point during pregnancy

	All	≥ 36 weeks
Vaginal planned	786 (69%)	391* (72%)
Caesarean planned	320 (28%)	148 (27%)
No reported plan	28 (3%)	1 (<1%)
Total	1134	540

72% compliant

^{*}Includes 3 women on ZDV monotherapy. all possible elite controllers with VL <50 copies/ml reported prior to ART initiation as well as at ≥36 weeks

ART, VL 50-399 at \geq 36 weeks

Consider caesarean section taking account of individual factors

50 women had a VL 50-399 copies/ml at ≥36 weeks:

- 24 planned for vaginal delivery
- 26 planned for caesarean section

A further 21 women with last reported VL 50-399 copies/ml at 0-35 weeks planned for vaginal delivery – possibly reflecting under-reporting of VL measurements

ART, $VL \ge 400$ at ≥ 36 weeks

Plan caesarean section


24 women had a VL ≥ 400 copies/ml at ≥36 weeks:

- •19 planned for caesarean section
 - 18 went on to have caesarean section
 - 1 had an unplanned vaginal delivery (see next slide)
- •3 planned for vaginal delivery
 - All 3 went on to have a caesarean section
- •1 woman was diagnosed during labour (see next slide)
- •1 woman did not book antenatally (see next slide)


Vaginal delivery in viraemic women

- Because of incomplete VL data it is unclear how many women delivered vaginally while viraemic but this could have been up to 29
- At least 3 women did so at ≥ 37 weeks:
 - 1 planning CS on ART had an unplanned vaginal birth at 37 weeks, VL 16,402 copies/mL
 - 1 HIV diagnosed during labour, VL 18,924 copies/mL
 - 1 known HIV positive but unbooked for antenatal care, VL post-delivery 57,000 copies/mL

Actual mode of delivery



Planned and actual mode of delivery



Conclusions

Limited data, particularly regarding VL, affected this audit but:

- Initial ART regimens were nearly all in accordance with guidelines
- Combination ART was initiated in over 80% of cases
- Only 29% of newly diagnosed women with CD4 <350 cells/mm³ started ART within 2 weeks
- Many women started ART late, and in most cases this was not explained by late booking

Conclusions

- More than half of deliveries were by CS
- 27% of women with VL <50 copies/ml measured at ≥36 weeks planned for CS
- National survey of management of pregnancy in women living with HIV, presented at autumn BHIVA 2014 found that some centres have a policy of maternal choice rather than recommending vaginal delivery for eligible women which should be reviewed

Recommendations

- Maternity and HIV services should review and agree pathways to ensure swift assessment and prompt ART initiation
- Clinicians should encourage women to plan vaginal delivery unless obstetric factors or insufficient virological control present a clear indication for CS
- Use of ART should be consistently reported to the Antiretroviral Pregnancy Registry (APR) to increase confidence of ART use in pregnancy

Acknowledgements

BHIVA wishes to thank all clinical services who reported data to NSHPC

Collaborators:

NSHPC: P Tookey, H Peters

BHIVA: S Raffe, H Curtis, Y Gilleece

BHIVA Audit & Standards Sub-Committee: A Freedman, B Angus, D Asboe, G Brough, A Brown, F Burns, D Chadwick, D Churchill, V Delpech, K Doerholt, Y Gilleece, P Gupta, A Molloy, J Musonda, C Okoli, O Olarinde, E Ong, S Raffe, M Rayment, A Rodger, C Sabin, A Sullivan, H Veerakathy

British HIV Association BHIVA

21st Annual Conference of the British HIV Association (BHIVA)

#BHIVA2015

21-24 April 2015

The Brighton Centre, Brighton, UK